Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexamethasone and Enzalutamide in mCRPC (DEXTER)
NCT02491411Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Sep 2015
- Primary completion
- Mar 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label, single-arm trial of dexamethasone in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Prostate-Specific Antigen Response Rate. Started Sep 2015; status: terminated.
02
Drugs
dexamethasone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02491411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02491411.